Tag Archives: bbT369

Thoughts on Regeneron Acquiring 2seventy bio’s Pipeline; How Could Regeneron Leverage its New Cell Therapy Pipeline?

On Tuesday, January 30, Regeneron announced (press release) the formation of Regeneron Cell Medicines based on an asset purchase agreement to acquire full development and commercialization rights to 2seventy bio’s pipeline, along with the clinical manufacturing capabilities, and related platform technologies.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

2seventy bio Announces Strategic Restructuring and Pipeline Reprioritization; Abecma’s US Revenue Guidance Lowered; Nick Leschly to Resign as CEO; Company to Expand Strategic Partnership with JW Tx

On September 12, 2023, 2seventy bio held a conference call (webcast / press release) announcing the strategic restructuring of the company’s business operations and R&D model. Measures include a 40% workforce reduction and a pipeline reprioritization and are driven by a projected decrease in Abecma’s (BMS / 2seventy BCMA CAR-T) revenue for 2023. Additionally, the company disclosed Nick Leschly’s decision to step down as CEO. On the same day, 2seventy announced the expansion of its collaboration with JW Tx adding 2 new assets from its pipeline: a solid tumor targeting TCR-T and a CAR-T for autoimmune diseases (press release). Below, Celltelligence provides insights on 2seventy’s new Abecma revenue projections for 2023 and the collaborative R&D model that the company aims to implement for its pipeline.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Abecma’s US Revenue Continues to Increase; DARIC33’s Data to Be Presented at ASGCT 2023; Manufacturing Capacity Ramping Up; 2seventy bio’s Q1 2023 Earnings Call Summary

On Wednesday, May 3, 2seventy bio held its Q1 2023 earnings call (press release) highlighting Abecma’s (BMS / 2seventy’s BCMA CAR-T) significant revenue increase. Moreover, management confirmed that early clinical data from DARIC33’s Ph1 PLAT-08 trial in r/r AML will be presented at ASGCT 2023 (May 16-20). Below, Celltelligence provides insights on 2seventy bio’s strategy to improve manufacturing capacity with a newly FDA-approved viral vector manufacturing suite, while discussing the main clinical milestones achieved by the assets in the pipeline.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Abecma’s sBLA Filing in ≥3L MM Remains on Track for Q1 2023; No Pipeline Updates; 2seventy bio Q4 2022 Earnings Summary; Gracell Acquires Patent Licenses from Seagen

On Thursday, March 16, 2seventy bio released its Q4 and FY 2022 financial results (press release) highlighting Abecma’s (BCMA CAR-T) increased US revenue. Additionally, management did not provide major milestone updates for 2023, with Abecma’s sBLA filing to the FDA for ≥3L MM still expected in Q1 2023. On the same day, Gracell reported (SEC Filing) a license agreement with Seagen, under which Gracell will have WW licenses to certain patents for clinical and preclinical research, as well as commercialization, of cell therapy products. Below, Celltelligence provides insights on Abecma’s potential market growth for 2023, while discussing the license agreement between Gracell and Seagen.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Precision BioSciences and 2seventy bio Provide Business Updates for 2023; JPM 2023 Analysis Day 2: Allogene and GSK

A series of cell therapy-related news items have been observed:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Abecma’s Ph3 KarMMa-3 Trial Meets Primary Endpoint; Potential Delays for bbT369 and SC-DARIC33; 2seventy bio Q2 2022 Earnings Call Summary

On Wednesday, August 10, 2seventy bio held their Q2 2022 earnings call (press release) highlighting positive topline results from Abecma’s (autologous BCMA CAR-T) Ph3 KarMMA-3 trial in ≥3L MM. Additionally, management provided updated data readouts for bbT369 (autologous CD20xCD79a dual CAR-T) and SC-DARIC33 (autologous CD33 CAR-T). Below, Celltelligence provides insights on Abecma’s LCM initiatives, while discussing potential clinical delays for bbT369 and SC-DARIC33.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Gilead (Kite) and 2seventy Bio Present Study Designs for their Next-Generation Assets Targeting Hematologic Malignancies; ASCO 2022 Analysis 3

ASCO 2022 Analysis 3: Gilead (Kite) and 2seventy bio reported study designs for their novel assets treating B cell malignancies. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Preclinical Results from 2seventy’s bbT369 and Cellectis’s UCART20x22 for r/r NHL; Switchable CAR-T Updates from Arcellx and Roche; AACR 2022 Analysis 2

AACR 2022 Analysis 2: Several preclinical updates were presented describing two different dual-targeting strategies for r/r NHL and two approaches for developing switchable CAR-Ts. Below, Celltelligence provides insights and context for each presentation. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

2seventy Extends Its Cash Runway Into 2025; Could Abecma Receive a ≥3L MM Approval Between 2023 – 2024? 2seventy Q4 2021 Earnings Summary

On Tuesday, March 22, 2seventy bio released their Q4 2021 results (press release) highlighting their extended cash runway into 2025 and Abecma’s (BCMA CAR-T) potential FDA approval in ≥3L MM between 2023 – 2024. Of note, no major updates were provided for other pipeline assets. Below, Celltelligence provides insights on how 2seventy could leverage their extended cash runway, while comparing Abecma’s potential approval in ≥3L MM with key competitor Carvykti (JNJ / Legend’s BCMA CAR-T).

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

2seventy Appoints Steven Bernstein as Their New CMO; Susan Abu-Absi Appointed as 2seventy’s Chief Technology and Manufacturing Officer

On Monday, February 14, 2seventy bio announced (press release) the appointment of Steven Bernstein as Chief Medical Officer (CMO) and Susan Abu-Absi as Chief Technology and Manufacturing Officer. Below, Celltelligence provides insights on how 2seventy could leverage Bernstein’s translational clinical background to bring novel assets into the clinic, while discussing the company’s decision to create a Chief Technology and Manufacturing Officer position. 

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.